VERAXA Biotech AG (NASDAQ: VRXA) has announced a collaboration with Ardigen S.A., an AI-driven bioinformatics company, to support the development of its BiTAC pipeline of T-cell engagers and future antibody-drug conjugates. The partnership will initially focus on developing AI-enabled tools to identify and prioritize synergistic dual-target combinations for VERAXA’s BiTAC platform, which is designed to improve tumor targeting while reducing off-target toxicity.
According to the press release, VERAXA believes that integrating artificial intelligence into its research and development strategy could enhance target selection by analyzing large preclinical and clinical datasets, including programs that demonstrated efficacy but failed because of toxicity. The company expects the collaboration to strengthen development of precision oncology therapies and improve long-term drug development success rates.
The partnership comes as the pharmaceutical industry increasingly turns to AI to streamline drug discovery and development. By harnessing AI’s ability to process vast amounts of data, VERAXA aims to identify promising drug candidates more efficiently and reduce the risk of late-stage failures. The BiTAC platform, which stands for Bispecific T-cell engager Antibody Conjugates, is a proprietary technology designed to engage the immune system to attack cancer cells while minimizing damage to healthy tissue.
VERAXA was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL), a world-renowned institution known for pioneering life science research. The company is building a pipeline of next-generation antibody-based therapeutics, including bispecific T cell engagers, bispecific ADCs, and other innovative formats.
The collaboration with Ardigen is expected to accelerate the development of these therapies by applying machine learning algorithms to analyze complex biological data. This could lead to the identification of novel target combinations that are more effective and safer than current approaches.
For more information about the partnership, visit the full press release at https://ibn.fm/GLFg2. For the latest news and updates on VERAXA Biotech, check the company’s newsroom at http://ibn.fm/VRXA.
This news story relied on content distributed by InvestorBrandNetwork (IBN). Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is VERAXA Biotech Partners with Ardigen to Integrate AI in Cancer Drug Development.